Company news

Rigel Pharmaceuticals, Inc. news in 2024

Rigel Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

December 1, 2024

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

November 6, 2024

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

November 4, 2024

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

October 30, 2024

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

October 23, 2024

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 3, 2024

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

September 4, 2024

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

September 2, 2024

Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

August 5, 2024

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

July 29, 2024

Rigel Announces Reverse Stock Split

June 24, 2024

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

June 23, 2024

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

June 13, 2024

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 22, 2024

Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

April 29, 2024

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

April 3, 2024

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

March 11, 2024

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 4, 2024

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

February 26, 2024

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

February 21, 2024

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

January 3, 2024

Calls in 2024

Decks in 2024